Video

Dr. Schlumbrecht on Remaining Challenges in Uterine Leiomyosarcoma

Matthew P. Schlumbrecht, MD, discusses remaining challenges in uterine leiomyosarcoma.

Matthew P. Schlumbrecht, MD, associate professor and co-director of Cancer Prevention and Control, Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses remaining challenges in uterine leiomyosarcoma.

Historically, uterine leiomyosarcoma has been a difficult tumor to treat, explains Schlumbrecht. Studies have not definitively shown that up front chemotherapy is effective. Additionally, a limited number of chemotherapy and targeted therapy has shown activity in the recurrent setting.

As such, the prognosis for women with this disease remains poor, says Schlumbrecht.

Going forward, identifying predictive biomarkers and underlying genetic mutations may help the field understand which patients are more likely to respond to treatment, concludes Schlumbrecht.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center